CRISPR RNPs and the Future of Cell and Gene Therapy

Download Article

region na1
portalId 1769030
formId 7d08e288-b33f-4e1c-bd5d-251262db95f1
target services-hubspot-form
Screenshot 2023-03-21 at 1.13.18 PM

As clustered regularly interspaced short palindromic repeats (CRISPR) therapies progress to the clinic, the key CRISPR editing components are primarily being delivered by recombinant virus, RNA, or as ribonucleoprotein (RNP), which is the active complex formed by the guide RNA and Cas9 protein. RNPs have several attractive properties as a delivery format, particularly in the manufacturing of ex vivo cellular therapies, the most rapidly growing segment of the CRISPR therapeutics market.

Download our article today.